Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant SHR1210 (PD-1) ± Apatinib ± S1 ± Oxaliplatin in Resectable Locally Advanced Gastric Cancer
NCT03878472Phase 2Completed
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Apr 2019
- Primary completion
- Jun 2022
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in gastric cancer (GC), sponsored by Qilu Hospital of Shandong University. Started Apr 2019; status: completed.
02
Drugs
camrelizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT03878472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03878472.